Security key
09203E105
Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (BDTX)
CUSIP: 09203E105
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 37,853,431
- Total 13F value
- $92,001,922
- Share change
- -1,059,083
- Put/Call ratio
- 42%
- SEC-reported price per share
- $2.43
- Number of holders
- 103
- Value change
- -$6,001,452
- Number of buys
- 59
- Number of sells
- 38
- Shares outstanding
- 58,000,000
Holder snapshot
7 facts
Show 1 more fact
Security identity
1 fact
Report period
Q4 2025
Institutions
103
Top holders
10
BDTX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Black Diamond Therapeutics, Inc. SEC filings
Black Diamond Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09203E105
Recent filing periods:
Ownership snapshot
Top reported holders of BDTX - Black Diamond Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BB BIOTECH AG
Disclosed value leader
T. Rowe Price Investment ...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 4.8%
13D/G row: BB BIOTECH AG
Showing 1-6 of 15 holder rows.
Quick read
BB BIOTECH AG leads the comparable SEC ownership view at 4.8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
BB BIOTECH AG
4.8%
BlackRock, Inc.
4.5%
Vestal Point Capital, LP
1.5%
T. Rowe Price Investment Manageme...
19%
NEA Management Company, LLC
7.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BB BIOTECH AG |
13D/G
|
4.8%
|
$4,373,675
2,733,547 shares
|
-$9,254,867 | 19 Mar 2025 |
| BlackRock, Inc. |
13D/G
13F
Company
|
4.5%
|
$4,037,634
2,523,521 shares
|
$0 | 31 Mar 2025 |
| Vestal Point Capital, LP |
13F
13D/G
Company
|
1.5%
from 13D/G
|
$21,034,500
5,550,000 shares
|
— | 30 Sep 2025 |
| T. Rowe Price Investment Management, Inc. |
13F
Company
|
19%
|
$40,721,000
10,744,107 shares
|
— | 30 Sep 2025 |
| NEA Management Company, LLC |
13F
Company
|
7.7%
|
$16,860,789
4,448,757 shares
|
— | 30 Sep 2025 |
| VANGUARD GROUP INC |
13F
Company
|
3.8%
|
$8,295,768
2,188,857 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
103
Shares
37,853,431
Rows available
103
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
89
Q4 2025 holders
103
Holder diff
14
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend